The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.
wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Differences between both versions are highlighted.
- Text added in the newer version is highlighted and underlined.
- Text removed in the newer version is highlighted and striked through.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text.
Read more.
Welcome to WikiGenes!
If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text.
Ideally this entry shall become one comprehensive and continuous article. Bulleted lists, for instance, were only used because it is impossible to automatically integrate independent facts into a continuous text.
Much of the current information on this page has been automatically compiled from Pubmed.
This precompiled information serves as a substrate and matrix to embed your contributions, but it is by no means the final word - Homo sapiens can do much better!
WikiGenes is a non-profit and open access community project - Read more.
Mechanisms by which PINK1 deficiency cause cellular dysfunction (reviewed in [3] include calcium dysregulation [4][5], direct or indirect effects on complex I respiratory function (Morais et al. EMBO Mol Med 1: 2009, 99-111)[5], and oxidative stress, which occur upstream of mitochondrial remodeling and autophagy [6][7].
Progress has been made in understanding some of the mechanisms of toxicity: Parkin is an E3 ubiquitin ligase and DJ-1 and PINK1 appear to protect against mitochondrial damage [8].
In a recent issue of Nature, two independent reports by and show that loss of Drosophila PINK1 leads to defects in mitochondrial function resulting in male sterility, apoptotic muscle degeneration, and minor loss of dopamine neurons that is rescued by overexpression of the ubiquitin E3 ligase, parkin[9].
PINK1 may act as a sensor for mitochondrial function/dysfunction. Functional mitochondria import and release proteolytically processed forms of PINK1 [11]. Failure of PINK1 processing by depolarized mitochondria triggers their removal by PARK2-dependent mitophagy [12]. In contrast, processed PINK1 signals neurodifferentiation and dendrite outgrowth [13].
PINK1 deficiency suppresses complex I respiratory function through direct (Morais et al. EMBO Mol Med 1: 2009, 99-111) or indirect mechanisms involving mitochondrial calcium dysregulation [5].
Generally, the T-cell clones have been obtained from immune donors, but J.R.L. Pink and F. Sinigaglia argue here that non-immune, human leukocyte antigen (HLA)-typed donors are a useful source of clones and antigen-presenting cells that can be used to assay systematically peptide-MHC associations [19].
The molecular mechanisms responsible for postpollination changes in floral scent emission were investigated in snapdragon cv Maryland True Pink and petunia cv Mitchell flowers using a volatile ester, methylbenzoate, one of the major scent compounds emitted by these flowers, as an example [20].
All sites of mutations were novel, suggesting that PINK1 may be the second most common causative gene next to parkin in parkinsonism with the recessive mode of inheritance [1].
PTEN-induced kinase 1 (PINK1) is a recently identified gene, mutations of which cause levodopa-responsive parkinsonism[21].
They found two novel PINK1 mutations: one was a homozygous deletion (13516-18118del) and the other a homozygous missense mutation (C388R) [14].
Naturally occurring non-coding antisense provides sophisticated mechanisms for diversifying genomes and we describe a human specific non-coding antisense expressed at the PINK1 locus (naPINK1) [24].
The observation of concordant regulation of svPINK1 and naPINK1 during in vivo mitochondrial biogenesis was confirmed using RNAi, where selective targeting of naPINK1 results in loss of the PINK1 splice variant in neuronal cell lines[24].
Genotyping these tags in a set of 576 Parkinson's disease patients and 514 controls did not demonstrate a case-control partition for allele or for haplotype and thus provides evidence against the existence of a common functional variants in PINK1 that has a strong influence on PD risk [25].
Downstream pathways modulated by PINK1 include phosphorylation of the HSP90-family member TRAP1/Hsp75 [26]and indirect effects on phosphorylation of HtrA2 [27]and Drp1(Sandebring in press).[7].
Several studies implicate PINK1 in regulation of oxidative stress. PINK1 loss of function is associated with increased ROS detected in human cells [6][28][29]and Drosophila [30]. PINK1 transcription may be upregulated as part of a FOXO-regulated ROS defense response [31].
Calcium dysregulation appears to be an upstream consequence of PINK1 loss of function. Mitochondria play a key role in buffering cytosolic calcium taking up calcium into the matrix through a membrane-potential dependent uniporter. A sodium-calcium antiporter releaases calcium back into the cytosol to regenerate buffering capacity. PINK1 deficient human and mouse neurons show defective antiporter activity and enhanced sensitivity to mitochondrial calcium overload [5]. Blocking mitochondrial calcium uptake protects cells expressing a PINK1 truncation mutant and A52T a-synuclein [4].
PINK1 loss of function promotes fission in cultured mammalian cells [32][6](Sandebring in press). [Ref]. This process may involve calcium-dependent activation of calcineurin, which dephosphorylates the fission protein Drp1(Sandebring in press), [Ref], and mitochondrial fragmentation is inhibited by antioxidants [6].
Abnormal cristae and decreased mitochondrial membrane potential have been consistently implicated in a variety of experimental models (Reviewed in Chu in press).[33]. PINK1 may associated with complexes of the mitochondrial electron transport chain and its loss of function may have direct effects on mitochondrial complex I function (Morais 2009), although indirect effects through substrate limitation have also been shown [5].
PINK1 levels modulate the mitochondrial fission-fusion balance, but differences are observed in Drosophila versus cultured human cells. In Drosophila, loss of PINK1 function causes enlarged mitochondria, complemented by enhancing Drp1 or suppressing Mfn/Opa [34][35][36]. In human cells, loss of PINK1 function causes mitochondrial fragmentation [32][6] (Sandebring in press), , reversed by dominant negative Drp1, Drp1 siRNA or Opa1/Mfn2 overexpression. The effects of PINK1 on mitochondrial dynamics may be indirect [34] (Sandebring in press). .
Mitochondrial fission and mitochondrial autophagy are coordinately upregulated in PINK1 loss of function neuronal cells [6]. Inhibiting either process exacerbates cell death, implying both processes as part of a compensatory process that isolates depolarized mitochondria (and presumably reduces ROS and calcium leakage). In lysosomal storage diseases, sustained deficits in lysosomal function result in accumulation of fragmented mitochondria with impaired calcium buffering and enhanced susceptibility to injury [37].
Protection against injury arising from PINK1 deficiency could be achieved through enhancement of compensatory adaptations (fission and autophagy), and do not necessarily imply that the normal role of PINK1 has been reconstituted by reversal of the primary deficit [3].
Parkin overexpression protects against the effects of PINK1 deficiency in multiple experimental systems [38][32][6]. Parkin has been shown to promote autophagy of depolarized mitochondria [39]. Parkin restores steady state mitochondrial morphology in PINK1 deficient cells by enhancing mitochondrial autophagy [6].
PINK1 is expressed abundantly in mitochondria rich tissues, such as skeletal muscle, where it plays a critical role determining mitochondrial structural integrity in Drosophila [24].
The physiological relevance of this observation is not yet clear, but it implies that a portion of PINK1 may be exported after processing in the mitochondria[40].
These results show that PINK1 is processed at the N terminus in a manner consistent with mitochondrial import, but the mature protein also exists in the cytosol[40].
To study the effect of PINK1 mutations on oxidative stress, we used primary fibroblasts and immortalized lymphoblasts from three patients homozygous for G309D-PINK1[41].
In addition, we show that PINK1 is detected in a proportion of Lewy bodies in cases of sporadic Parkinson's disease and Parkinson's disease associated with heterozygous mutations in the PINK1 gene, which are clinically and pathologically indistinguishable from the sporadic cases [16].
We demonstrated that, on proteasome inhibition with MG-132, PINK1 and other mitochondrial proteins localized to aggresomes [43].
Both recombinant enzymes preferentially phosphorylate the artificial substrate histone H1 exclusively at serine and threonine residues, demonstrating that PINK1 is indeed a protein serine/threonine kinase [10].
Furthermore, co-expression of wild-type DJ-1 and PINK1 suppresses neurotoxin 1-methyl-4-phenylpyridinium (MPP(+))-induced death of dopaminergic SH-SY5Y cells [44].
CONCLUSIONS: Heterozygous PINK1 mutations may predispose to PD, as was previously suggested by the presence of dopamine hypometabolism in asymptomatic mutation carriers [45].
In a large Saudi family with PD with at least 3 consanguineous marriages between first cousins, we detected a threonine to methionine substitution at codon 313 (T313M) PINK1 mutation that affected the kinase domain [46].
Mutations in genes encoding both DJ-1 and pten-induced kinase 1 (PINK1) are independently linked to autosomal recessive early-onset familial forms of Parkinson's disease (PD) [44].
INTERVENTIONS: Analysis of clinical characteristics and mutation analysis of the parkin and PTEN-induced kinase (PINK1) genes by direct sequencing and gene-dosage analysis using the multiplex ligation-dependent probe amplification technique [47].
Here we show that mutations in PINK1 (PTEN-induced kinase 1) are associated with PARK6[2].
Overexpression of wild-type PINK1 also reduced the levels of cleaved caspase-9, caspase-3, caspase-7, and activated poly(ADP-ribose) polymerase under both basal and staurosporine-induced conditions [48].
Recruiting new families will help cloning the defective genes at PARK6 and PARK7 loci [49].
We here summarize the results of genetic investigations on a series of 82 parkinsonian patients from 60 families in Taiwan. We found 13 parkin patients in 7 families (12%), 2 PINK1 sibs from 1 family, and 1 LRRK2 patient from 1 family with I2012T mutation [50].
Analytical, diagnostic and therapeutic context of PINK1
Cell culture studies suggest that PINK1 is mitochondrially located and may exert a protective effect on the cell that is abrogated by the mutations, resulting in increased susceptibility to cellular stress [2].
To test for the presence of exon rearrangements in PINK1, we established a new quantitative duplex PCR assay [51].
We performed sequence analysis of all the coding and exon-intron junctions of the PINK1 using specific primer sets [15].
We describe two unrelated cases with PINK1 mutations (homozygous nonsense and heterozygous missense) that highlight issues regarding the role of heterozygous mutations and the utility of genetic screening in patient care[52].
Using immunohistochemistry and western blotting we were able to demonstrate that PINK1 is a ubiquitous protein expressed throughout the human brain and it is found in all cell types showing a punctate cytoplasmic staining pattern consistent with mitochondrial localization [16].
References
Novel PINK1 mutations in early-onset parkinsonism. Hatano, Y., Li, Y., Sato, K., Asakawa, S., Yamamura, Y., Tomiyama, H., Yoshino, H., Asahina, M., Kobayashi, S., Hassin-Baer, S., Lu, C.S., Ng, A.R., Rosales, R.L., Shimizu, N., Toda, T., Mizuno, Y., Hattori, N. Ann. Neurol. (2004) [Pubmed]
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R., González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., Harvey, R.J., Dallapiccola, B., Auburger, G., Wood, N.W. Science (2004) [Pubmed]
PINK1 mutations in sporadic early-onset Parkinson's disease. Tan, E.K., Yew, K., Chua, E., Puvan, K., Shen, H., Lee, E., Puong, K.Y., Zhao, Y., Pavanni, R., Wong, M.C., Jamora, D., de Silva, D., Moe, K.T., Woon, F.P., Yuen, Y., Tan, L. Mov. Disord. (2006) [Pubmed]
PINK1 protein in normal human brain and Parkinson's disease. Gandhi, S., Muqit, M.M., Stanyer, L., Healy, D.G., Abou-Sleiman, P.M., Hargreaves, I., Heales, S., Ganguly, M., Parsons, L., Lees, A.J., Latchman, D.S., Holton, J.L., Wood, N.W., Revesz, T. Brain (2006) [Pubmed]